Stock AnalizIncyte (INCY) earnings for the quarter ended September 2026: EPS beats estimates
Incyte reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at -$3.60 against the analysts’ average forecast of -$3.87, a beat of 6.9%.
Revenue for the quarter was $1.56 billion, up 14.0% from $1.37 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 0.1% on the first trading day after the report.
The last four quarters
Incyte has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | -$3.60 | -$3.87 | +6.9% | +14% | −0.1% |
| Jun 2026 | $3.09 | $2.15 | +44.0% | — | +6.9% |
| Mar 2026 | $1.81 | $1.34 | +35.1% | +21% | +3.5% |
| Sep 2025 | $2.26 | $1.64 | +38.0% | +20% | −3.1% |
What comes next
Analysts expect EPS of $1.97 for the next quarter on average and $3.46 for the fiscal year ending December 31, 2026.
The average analyst price target is $131.50, 9% above the current price of $120.97.
Valuation and score
Incyte scores 2.8 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 64.3, and its intrinsic value under moderate assumptions is about 48% below the current market value. Full Incyte analysis with 10 years of financials
Frequently asked questions
What was Incyte’s EPS for the quarter ended September 2026?
-$3.60 adjusted per share, against an analyst consensus of -$3.87.
How much revenue did Incyte report?
$1.56 billion, up 14.0% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.